Evidence map›Paper›PMID 28487390›Full record

ArticleJournal of the American Heart Association2017

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Pu Qin, Pelin Arabacilar, Roberta E Bernard, Weike Bao, Alan R Olzinski, Yuanjun Guo, Hind Lal, Stephen H Eisennagel, Michael C Platchek, Wensheng Xie and 22 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Characterization of a robust mouse model of heart failure with preserved ejection fraction.American journal of physiology. Heart and circulatory physiology · 2023
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. The Multifaceted Roles of Proline in Cell Behavior.Frontiers in cell and developmental biology · 2021
    Review
  13. Article
  14. Article
  15. Aminoacyl-tRNA synthetase inhibition activates a pathway that branches from the canonical amino acid response in mammalian cells.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 5 institutions in 2 countries.

Pu QinHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA pu.2.qin@gsk.com.
Pelin ArabacilarHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Roberta E BernardHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Weike BaoHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Alan R OlzinskiHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Yuanjun GuoBasic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN.
Hind LalBasic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN.
Stephen H EisennagelHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Michael C PlatchekTarget and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
Wensheng XieTarget and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
Julius Del RosarioHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Mohamad NayalHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Quinn LuTarget and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
Theresa RoethkeHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Christine G SchnackenbergHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Fe WrightPreclinical and Translational Imaging, Platform Technology and Science, GlaxoSmithKline, King of Prussia, PA.
Michael P QuailePreclinical and Translational Imaging, Platform Technology and Science, GlaxoSmithKline, King of Prussia, PA.
Wendy S HalseyTarget and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
Ashley M HughesTarget and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
Ganesh M SatheTarget and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
George P LiviTarget and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
Robert B KirkpatrickPipeline Future's Group, GlaxoSmithKline, King of Prussia, PA.
Xiaoyan A QuComputational Biology, Projects Clinical Platforms and Sciences, GlaxoSmithKline, King of Prussia, PA.
Deepak K RajpalComputational Biology, Projects Clinical Platforms and Sciences, GlaxoSmithKline, King of Prussia, PA.
Maria Faelth SavitskiCellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA.
Marcus BantscheffCellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA.
Gerard JobertyCellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA.
Giovanna BergaminiCellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA.
Thomas L ForceBasic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN.
Gregory J GattoHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Erding HuHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
Robert N WilletteHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
GlaxoSmithKline (Netherlands) · NLGlaxoSmithKline (United States) · USPathways Behavioral Services · USVanderbilt University · USTarget (United States) · US

Funding

Signaling Mechanisms Governing Myocardial Fibrosis in Diseased HeartR01HL133290 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Hind Lal · 2017 to 2026
$3.6M
Heart Failure in Cancer PatientsR01HL119234 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LAL, HIND · 2014 to 2017
$1.6M
NHLBI NIH HHS R01 HL119234NHLBI NIH HHS R01 HL133290
6 · The paper itself

Abstract

backgroundThe amino acid response (AAR) is an evolutionarily conserved protective mechanism activated by amino acid deficiency through a key kinase, general control nonderepressible 2. In addition to mobilizing amino acids, the AAR broadly affects gene and protein expression in a variety of pathways and elicits antifibrotic, autophagic, and anti-inflammatory activities. However, little is known regarding its role in cardiac stress. Our aim was to investigate the effects of halofuginone, a prolyl-tRNA synthetase inhibitor, on the AAR pathway in cardiac fibroblasts, cardiomyocytes, and in mouse models of cardiac stress and failure. METHODS AND

resultsConsistent with its ability to inhibit prolyl-tRNA synthetase, halofuginone elicited a general control nonderepressible 2-dependent activation of the AAR pathway in cardiac fibroblasts as evidenced by activation of known AAR target genes, broad regulation of the transcriptome and proteome, and reversal by l-proline supplementation. Halofuginone was examined in 3 mouse models of cardiac stress: angiotensin II/phenylephrine, transverse aortic constriction, and acute ischemia reperfusion injury. It activated the AAR pathway in the heart, improved survival, pulmonary congestion, left ventricle remodeling/fibrosis, and left ventricular function, and rescued ischemic myocardium. In human cardiac fibroblasts, halofuginone profoundly reduced collagen deposition in a general control nonderepressible 2-dependent manner and suppressed the extracellular matrix proteome. In human induced pluripotent stem cell-derived cardiomyocytes, halofuginone blocked gene expression associated with endothelin-1-mediated activation of pathologic hypertrophy and restored autophagy in a general control nonderepressible 2/eIF2α-dependent manner.

conclusionsHalofuginone activated the AAR pathway in the heart and attenuated the structural and functional effects of cardiac stress.

Indexed as

Stress, PhysiologicalAmino AcidsAmino Acyl-tRNA SynthetasesAnimalsAutophagyCells, CulturedDisease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsFibroblastsFibrosisHeart FailureHumansHypertrophy, Left VentricularInduced Pluripotent Stem CellsMaleAmino AcidsAmino Acyl-tRNA SynthetasesEIF2AK4 protein, humanEif2ak4 protein, mouseEnzyme InhibitorshalofuginonePiperidinesProtein Serine-Threonine KinasesProtein Synthesis InhibitorsQuinazolinonesamino acid responsefibrosishalofuginoneheart failurehypertrophy

Identifiers

PMID28487390
PMCPMC5524058
OpenAlexW2613469768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.